AAV manufacturing with stable producer cells for industrial scale vector production

As gene therapy moves towards more frequent indications with large patient cohorts or systemic administration, incomparably higher amounts of vector material are required. Stable helper virus-free AAV producer cell lines are the technology of choice to elevate the manufacturing scale of AAV gene therapy vectors to this next level. 

The stable ELEVECTA^® producer platform offers an “easy-to-scale” production platform in which AAV production is simply started via induction as all components necessary for AAV production are stably integrated in the cells. The platform makes AAV production as simple as monoclonal antibody production.

• Eliminate any transient transfection/helper virus infection step from your AAV production process
• Achieve reliable AAV production by simple induction of suspension producer cells
• Easy scale-up of AAV production instirred tank bioreactors
• Increase AAV production in stirred tank bioreactor up to E15 vg/L using an intensified process
• Free choice of stable producer cell line based on HEK 293 or CAP^® cells.

Ben Hudjetz

Senior Scientist, Cell Line Development, CEVEC, now part of Cytiva

Ben Hudjetz is a Senior Scientist in the Cell Line Development Department at CEVEC. He holds a PhD in Cell Biology and Virology from the Heinrich-Pette-Institute (University of Hamburg). Before joining CEVEC in 2017 he worked on the development of nucleic acid-based drugs. In his current position his main scientific focus is the development and optimization of CEVEC’s ELEVECTA stable AAV producer cell lines based on HEK293 cells.

Watch now

SPEAKERS

Ben Hudjetz

Senior Scientist, Cell Line Development, CEVEC, now part of Cytiva

You might also like

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes

21 May

Watch

Improving AAV productivity and packaging efficiency for transient and producer cell lines through plasmid engineering

Lisa Prendergast

19 March

Watch

Meeting manufacturing demand: robust scale-up of an AAV suspension process to 1,000L

Qingrui You, Peiqing Zhang

29 October

Watch

Commercial-scale manufacture of lentivirus for ex vivo and in vivo therapies

Rachel Legmann, Michelle Yen Tran

28 March

Watch

Increasing efficiency in AAV-based gene therapy production: platform optimization with multiserotype AAV affinity capture

Nicolas Laroudie, Tiago Albano

27 March

Watch